Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
At CROI Tim Horn speaks with David Hardy, MD, from Cedars Sinai Medical Center, about new HIV treatments—including two entry inhibitors.
Tim Horn speaks with David Hardy, MD, from Cedars Sinai Medical Center in Los Angeles, about new HIV treatments at annual conference.
David Evans speaks with Michael Silverberg about the latest research on cancer risk in people with HIV, and strategies for reducing it.
David Evans speaks with Mitchell Warren, from the AIDS Vaccine Advocacy Coalition in New York City, about the state of prevention research.
At annual conference, David Evans speaks with Suzanne Ingle about factors affecting the roll out of HIV treatment in Southern Africa.
At CROI, David Evans speaks with Scott Letendre, MD about the relationship of HIV levels in the brain versus the blood.
At CROI, David Evans speaks with Ronald Ellis, MD, PhD about factors that protect the brain from
Survival among HIV-positive men who keep their CD4 counts above 500 cells for at least three years is comparable with general population.
About one of every six new HIV cases diagnosed in 2007 involved virus with antiretroviral (ARV) drug-resistance mutations.
At CROI, David Evans speaks with Grace McComsey, MD about the causes of bone loss in people living
with HIV, and what can be done about it.
People living with HIV face a higher risk of bone fractures than people of similar ages in the general population.
Vitamin D insufficiency is common among people living with HIV in the United States—although not necessarily more so compared with the...
Hepatitis C virus (HCV) treatment—when successful—offers survival benefits over and above reductions in liver disease among people...
People with undetectable HIV levels in the blood are also likely to have undetectable levels in the brain, according to a study presented Febr...
People who are able to maintain CD4 counts above 350 have a lower risk of developing brain damage. This conclusion, based on an analysis of da...
Truvada (tenofovir and emtricitabine) is more likely to lead to bone loss than Epzicom (abacavir and lamivudine); in addition, Norvir (ritonav...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.